Alzheimer’s disease (AD) is a progressive neurodegenerative disorder with no effective treatments or known biomarkers for definitive diagnosis, substantiating the need for early detection and intervention. This project employs Magnetic Resonance Spectroscopy to quantify neurochemical changes in the TgF344-AD rat model of AD in response to early versus late administration of a common non-steroidal anti-inflammatory drug, specifically addressing the critical question of treatment timing. Preliminary results suggest the TgF344-AD rat recapitulates most neurochemical features of human AD and that early treatment is more effective than late treatment at mitigating disease-related neurochemical changes.
This abstract and the presentation materials are available to members only; a login is required.